Skip to the content

Mannan-Binding Lectin Pathway Function Test (C4b)

Test Code: 34
Expand All Collapse All
Clinical Utility

Deficiency in either MBL or MASP-2 appears to predispose individuals to serious infections (e.g. pneumonitis, sepsis, osteomyelitis, gastroenteritis and meningitis) especially during childhood before the adaptive immunity has fully developed.

Procedure

Enzyme Immunoassay (EIA). MBL pathway function is indirectly monitored by determining the the specific C4b-depositing capacity of patient sera with an anti-human C4 monoclonal antibody. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.

5-7 business days from receipt of specimen

Specimen Type Order Code CPT Code NY Approved Volume Assay Range Special Instructions
serum 34 86161 Yes 2 mL (min. 100 uL) The assay range is approximately 135 to 3100. Results less than 200 ng/mL indicate deficiency. This range is the mean plus 3 standard deviations with sera obtained from a population of deficient individuals
  • Collect 1 mL, no special shipping requirements.
  • Stability 1 week ambient, 4 weeks refrigerated, >3 months frozen (can go through 4 freeze/thaw cycles).

The assay range is approximately 135 to 3100. Results less than 200 ng/mL indicate deficiency. This range is the mean plus 3 standard deviations with sera obtained from a population of deficient individuals

Specimens are approved for testing in New York only when indicated in the Specimen Information field above.

The CPT codes provided are based on Viracor Eurofins' interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for general informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor Eurofins assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.

References

Kilpatrick, D.C. Mannan-binding lectin and its role in innate immunity. Transfus.  Med. 2002; 12(6):335-352.

Kilpatrick, D.C. Mannan-binding lectin: clinical significance and applications.  Biochim. Biophys. Acta 2002; 1572:401-413.

Stengaard-Pederson, K. et al. Inherited deficiency of mannan-binding lectinassociated serine protease 2. N. Engl. J. Med. 2003; 349 (6):554-560.

Petersen, S. V. et al. An assay for the mannan-binding lectin pathway of complement activation. J. Immunol. Methods 2001; 257:107-116.

Moller-Kristensen, M. et al. Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals. J. Immunol. Methods 2003; 282:159-167.

Kirschfink, M. and Mollnes, T.E. Modern complement analysis. Clin. Diag. Lab. Immunol. 2003; 10:982-989.

Connect with us